Aliases & Classifications for Vitreous Detachment

MalaCards integrated aliases for Vitreous Detachment:

Name: Vitreous Detachment 12 43 15 17 71
Posterior Vitreous Detachment 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9726
MeSH 43 D020255
NCIt 49 C50807
SNOMED-CT 67 53772007
ICD10 32 H43.81
UMLS 71 C0042907 C0423361

Summaries for Vitreous Detachment

MalaCards based summary : Vitreous Detachment, also known as posterior vitreous detachment, is related to branch retinal artery occlusion and macular retinal edema, and has symptoms including eye manifestations An important gene associated with Vitreous Detachment is PLAT (Plasminogen Activator, Tissue Type), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Degradation of the extracellular matrix. The drugs Bevacizumab and Temazepam have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and cortex.

Wikipedia : 74 A posterior vitreous detachment (PVD) is a condition of the eye in which the vitreous membrane separates... more...

Related Diseases for Vitreous Detachment

Diseases related to Vitreous Detachment via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 branch retinal artery occlusion 30.4 VEGFA PLG
2 macular retinal edema 30.3 VEGFB VEGFA PLG KCNMA1
3 central retinal artery occlusion 30.3 VEGFA PLG PLAT
4 central retinal vein occlusion 30.3 VEGFA PLG PLAT
5 vascular disease 30.2 VEGFA PLG PLAT FN1
6 disseminated intravascular coagulation 30.2 PLG PLAT FN1
7 preretinal fibrosis 30.2 VEGFA FN1 DPT
8 exudative vitreoretinopathy 1 29.9 VEGFB VEGFA FN1
9 neovascular glaucoma 29.8 VEGFB VEGFA PLG
10 kuhnt-junius degeneration 29.7 VEGFB VEGFA PLG FAM187A
11 retinal vascular disease 29.7 VEGFB VEGFA PLG FN1
12 retinal artery occlusion 29.6 VEGFB VEGFA PLG
13 macular holes 29.6 VEGFA PLG OPTC LHFPL5 KCNMA1 FN1
14 endophthalmitis 29.3 VEGFB VEGFA PLG LAMA3
15 macular degeneration, age-related, 1 28.6 VEGFB VEGFA PLG OPTC LAMA3 KCNMA1
16 retinal detachment 10.8
17 myopia 10.5
18 microvascular complications of diabetes 5 10.5
19 hydrops, lactic acidosis, and sideroblastic anemia 10.5
20 basal ganglia cerebrovascular disease 10.5 PLG PLAT
21 anterior cerebral artery infarction 10.5 PLG PLAT
22 ligneous conjunctivitis 10.4 PLG PLAT
23 lipodermatosclerosis 10.4 VEGFA PLAT
24 basilar artery occlusion 10.4 PLG PLAT
25 acute cor pulmonale 10.4 PLG PLAT
26 acute pulmonary heart disease 10.4 PLG PLAT
27 marantic endocarditis 10.4 PLG PLAT
28 brain stem infarction 10.4 PLG PLAT
29 diabetic macular edema 10.4
30 thoracic outlet syndrome 10.4 PLG PLAT
31 inferior myocardial infarction 10.4 PLG PLAT
32 cataract 10.4
33 refractive error 10.4
34 conversion disorder 10.4 PLG PLAT
35 intracranial embolism 10.4 PLG PLAT
36 erysipeloid 10.4 PLG FN1
37 basilar artery insufficiency 10.4 PLG PLAT
38 chorioretinal scar 10.4 VEGFA KCNMA1
39 macular degeneration, age-related, 2 10.4 VEGFA PLAT
40 middle cerebral artery infarction 10.4 PLG PLAT
41 microvascular complications of diabetes 1 10.3
42 microvascular complications of diabetes 2 10.3
43 optic disk drusen 10.3 OPTC KCNMA1
44 carotid artery thrombosis 10.3 PLG PLAT
45 degenerative myopia 10.3 VEGFA DPT
46 occlusion precerebral artery 10.3 PLG PLAT
47 pulmonary artery disease 10.3 VEGFA PLG PLAT
48 retinal vein occlusion 10.3
49 hepatic veno-occlusive disease 10.3 VEGFA PLG PLAT
50 obstructive hydrocephalus 10.3 PLG PLAT

Graphical network of the top 20 diseases related to Vitreous Detachment:



Diseases related to Vitreous Detachment

Symptoms & Phenotypes for Vitreous Detachment

UMLS symptoms related to Vitreous Detachment:


eye manifestations

Drugs & Therapeutics for Vitreous Detachment

Drugs for Vitreous Detachment (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2
Temazepam Approved, Investigational Phase 4 846-50-4 5391
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
5 Angiogenesis Inhibitors Phase 4
6 Antineoplastic Agents, Immunological Phase 4
7 Anti-Anxiety Agents Phase 4
8 Tranquilizing Agents Phase 4
9 Neurotransmitter Agents Phase 4
10 Hypnotics and Sedatives Phase 4
11 GABA Agents Phase 4
12 Psychotropic Drugs Phase 4
13 Central Nervous System Depressants Phase 4
14 GABA Modulators Phase 4
15 Antiemetics Phase 4
16 HIV Protease Inhibitors Phase 4
17 Gastrointestinal Agents Phase 4
18 Hormone Antagonists Phase 4
19
protease inhibitors Phase 4
20 BB 1101 Phase 4
21 Autonomic Agents Phase 4
22 Anti-Inflammatory Agents Phase 4
23 Antineoplastic Agents, Hormonal Phase 4
24 glucocorticoids Phase 4
25 Hormones Phase 4
26
Ranibizumab Approved Phase 2 347396-82-1 459903
27
Fibrinolysin Investigational Phase 2 9004-09-5
28 Pharmaceutical Solutions Phase 2
29 Fibrinolytic Agents Phase 2
30 Plasminogen Phase 1, Phase 2
31
Dipivefrin Approved 52365-63-6 3105
32
Triamcinolone Approved, Vet_approved 124-94-7 31307
33
tannic acid Approved 1401-55-4
34
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
35 Tetrahydrozoline
36 Proxymetacaine
37 Triamcinolone hexacetonide
38 Triamcinolone diacetate
39 triamcinolone acetonide
40 Tissue Plasminogen Activator

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Combined Therapy in ARMD - Retrospective Case Series Completed NCT00805649 Phase 4 dexamethasone;bevacizumab;triamcincolone
2 A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients. Unknown status NCT00908778 Phase 3 Vitreosolve;Vitreosolve
3 Resolution of Vitreomacular Adhesion (VMA) Associated With Neovascular Age Related Macular Degeneration (AMD) With Intravitreal Microplasmin Unknown status NCT00996684 Phase 2 Microplasmin;Placebo control
4 An Open-label Assessment of Intravitreous Injections of Vitrase (Hyaluronidase for Injection) for Inducing Posterior Vitreous Detachment in Subjects With Moderate to Severe Non-proliferative Diabetic Retinopathy Completed NCT00198471 Phase 2 Vitrase
5 A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of DME. Completed NCT00412451 Phase 2 ocriplasmin
6 A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of Vitreomacular Traction (VMT). Completed NCT00435539 Phase 2 ocriplasmin;ocriplasmin;Sham Comparator
7 An Open Label, Single Centre Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion Completed NCT01055535 Phase 2 Microplasmin
8 Posterior Vitreous Detachment (PVD) Assessment During Dual RVO Lucentis Evaluations (PADDLE Study) Completed NCT00831350 Phase 2 Ranibizumab
9 A Phase 2, Randomised, Double Masked, Sham Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects With Non-proliferative Diabetic Retinopathy (NPDR) Active, not recruiting NCT02681809 Phase 2 ocriplasmin 0.0625mg;ocriplasmin 0.125mg;Sham injection
10 A Multicenter, Randomized, Double Masked, Placebo Controlled, Sequential Dose Response Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD) Terminated NCT00348439 Phase 2 Plasmin;Vehicle
11 An Open Label Sequential Dose Response Observational Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD) Terminated NCT00347646 Phase 1, Phase 2 Plasmin
12 Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema Terminated NCT01194674 Phase 1, Phase 2 Microplasmin
13 Partial Posterior Hyaloidectomy in Macular Surgery : A Modified Procedure of Vitrectomy to Prevent Retinal Break Related to Induction of a Posterior Vitreous Detachment Completed NCT01454466 Phase 1
14 A Phase 1 Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of Intravitreal ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment Recruiting NCT03780972 Phase 1 ONL1204
15 Vitreopapillary Traction and Optic Disc Morphology in Healthy Subjects, Vitreomacular Traction Patients and Glaucoma Patients Unknown status NCT02290795
16 Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation Unknown status NCT00673296 Intravitreal Bevacizumab
17 Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy Completed NCT01256632 Ranibizumab
18 A Prospective Randomized Controlled Trial Evaluating the Safety and Efficacy of YAG Vitreolysis Versus Sham for Symptomatic Weiss Ring Due to Posterior Vitreous Detachment Completed NCT02897583
19 Ultrastructure Analysis of Excised Internal Limiting Membrane in Eyes of Highly Myopia With Myopic Traction Maculopathy Completed NCT02528058
20 Randomized Trial of Laser Ablation for Highly Symptomatic Floaters Completed NCT01970267
21 Assessment of Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal Completed NCT01474655
22 OCT Documents Vitreo-papillary Traction Completed NCT03460600
23 Vitrectomy Without Laser or Gas Tamponade for Optic Disc Pit Maculopathy Completed NCT01340703
24 Evaluation of Blood-retinal Barrier Functional Alterations by Optical Coherence Tomography Completed NCT01220804
25 High-frequency-ultrasound Annular Arrays for Small Animal and Ophthalmic Imaging Completed NCT00633854
26 Intravitreal Administration of Ranibizumab Combined With Intravitreous Injection of Expansile Gas and Induction of Posterior Vitreous Detachment in Treatment of Exudative AMD With Posterior VMA: a Pilot, Open Label, Comparative Study Completed NCT01291121
27 Vitrectomy for Persistent Macular Edema in Branch Retinal Vein Occlusion Completed NCT00685490
28 Phase 1 Study of Optical Coherence Tomography Images to Identify the Prevalence of Vitreomacular Adhesion and Associated Maculopathies Completed NCT02160340
29 High-frequency-ultrasound Annular Arrays for Ophthalmic Imaging Completed NCT01415037
30 Extent of Internal Limiting Membrane Removal and Its Impact on Outcomes of Macular Hole Surgery Completed NCT02010138
31 Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy Completed NCT03208205
32 Comparing the Surgical Outcomes of Internal Limiting Membrane Peeling-reposition Versus Peeling in Idiopathic Macular Holes: A Randomized Controlled Trial Completed NCT03020459 Brilliant Blue G
33 Perfluorocarbone Liquids for Tamponading Lower Retinal Breaks to Achieve Retinal Reattachment in Eyes of Retinal Detachment With Proliferative Vitreoretinopathy Completed NCT04168255
34 Role of Intraoperative Dexamethasone Implant in Improving Outcome of Taut Posterior Hyaloid Removal in Diabetic Macular Edema Completed NCT01698788 Dexamethasone Drug delivery system (Ozurdex)
35 Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies Completed NCT00408720
36 Influence of Posterior Vitreous Detachment on Retinal Detachment After Lens Surgery in Myopic Eyes Recruiting NCT03152747
37 YAG Laser Vitreolysis of Symptomatic Vitreal Floaters Recruiting NCT03970148
38 Vitreomacular Interface Abnormalities Indiabetic Retinopathy Using Ocular Coherence Tomography Not yet recruiting NCT03686436
39 Effect on the Vitreous of the Not Complicated Surgery of the Cataract to the Emmetropic Patient Terminated NCT02783209
40 Evaluation of the Role of Intravitreal Injection of TPA in Treatment of Refractory Diabetic Macular Edema Terminated NCT01141881 Tissue Plasminogen Activator,bevacizumab ,follow up
41 Intravitreal Injection of Expansile Sulfa Hexafluoride Gas for Symptomatic Vitreomacular Adhesion Withdrawn NCT02001701

Search NIH Clinical Center for Vitreous Detachment

Cochrane evidence based reviews: vitreous detachment

Genetic Tests for Vitreous Detachment

Anatomical Context for Vitreous Detachment

MalaCards organs/tissues related to Vitreous Detachment:

40
Eye, Retina, Cortex, Endothelial, Brain, Testes, Heart

Publications for Vitreous Detachment

Articles related to Vitreous Detachment:

(show top 50) (show all 1284)
# Title Authors PMID Year
1
Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion. 54 61
18040240 2007
2
The effect of tissue plasminogen activator on premacular hemorrhage. 54 61
11195747 2001
3
Retinal tear and posterior vitreous detachment following repetitive transcranial magnetic stimulation for major depression: A case report. 61
31884185 2020
4
Posterior Vitreous Detachment: Methods for Detection. 61
32033710 2020
5
Accuracy of Spectral-Domain OCT of the Macula for Detection of Complete Posterior Vitreous Detachment. 61
31864940 2020
6
Evaluation of posterior vitreous detachment using ultrasonography and optical coherence tomography. 61
31301107 2020
7
Resolution of optic disc pit-associated macular retinoschisis after topical carbonic anhydrase inhibitor treatment: Report of a case. 61
32019335 2020
8
OUTCOME OF ACUTE NONTRAUMATIC VITREOUS HEMORRHAGE IN HEALTHY PATIENTS. 61
30300268 2020
9
RETINAL TEARS DUE TO PICKLEBALL INJURY. 61
31971926 2020
10
Using the Retrobulbar Spot Sign to Assist in Diagnosis and Management of Central Retinal Artery Occlusions. 61
31228289 2020
11
Objective assessment of YAG laser vitreolysis in patients with symptomatic vitreous floaters. 61
31988795 2020
12
Vitreous albumin redox state in open-angle glaucoma patients and controls: a pilot study. 61
31925660 2020
13
Intrachoroidal cavitation in myopic eyes. 61
31300972 2020
14
Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern®. 61
31757500 2020
15
FIRST-IN-HUMAN CLINICAL STUDY TO INVESTIGATE THE EFFECTIVENESS AND SAFETY OF PARS PLANA VITRECTOMY SURGERY USING A NEW HYPERSONIC TECHNOLOGY. 61
30358763 2020
16
COMPARING INTRAVITREAL AIR AND GAS FOR THE TREATMENT OF VITREOMACULAR TRACTION. 61
31876891 2019
17
Impact of Posterior Vitreous Detachment on Treatment Outcomes in Diabetic Macular Edema. 61
31982388 2019
18
Swept-source optical coherence tomography features of regressed macular retinoblastoma. 61
31755441 2019
19
Pars plana vitrectomy combined with scleral buckle versus pars plana vitrectomy for giant retinal tear. 61
31840810 2019
20
Comparison of Observation Versus Vitrectomy for Patients With Hemorrhagic Posterior Vitreous Detachment. 61
31755980 2019
21
Complete Posterior Vitreous Detachment Reduces the Need for Treatment of Diabetic Macular Edema. 61
31755977 2019
22
[Vitreomacular Traction Following Anti-VEGF Therapy - Two Cases]. 61
29179221 2019
23
Spontaneous disappearance and recurrence of impending macular hole: a case report. 61
31733654 2019
24
Structural Retinal Assessment Using Optical Coherence Tomography and Fundus Fluorescein Angiography in Systemic Lupus Erythematosus Patients. 61
31688343 2019
25
PREOPERATIVE VITREORETINAL INTERFACE ABNORMALITIES ON SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY AS RISK FACTOR FOR PSEUDOPHAKIC CYSTOID MACULAR EDEMA AFTER PHACOEMULSIFICATION. 61
30157113 2019
26
Persistent vitreous hemorrhage after intravitreal injection of dexamethasone intravitreal implant in patients with diabetic macular edema. 61
31942436 2019
27
Anterior Lens Capsule Transplantation for Acquired Optic Disc Pit Maculopathy. 61
31671198 2019
28
FULL DIAGNOSTIC VITRECTOMY WITH POSTERIOR VITREOUS DETACHMENT INDUCTION FOR THE DIAGNOSIS OF VITRITIS DUE TO UNCERTAIN ETIOLOGY. 61
30005004 2019
29
Evaluation of Systematic Reviews of Interventions for Retina and Vitreous Conditions. 61
31600387 2019
30
Comment on: The role of posterior vitreous detachment on the efficacy of anti-vascular endothelial growth factor intravitreal injection for treatment of neovascular age-related macular degeneration. 61
31546569 2019
31
Reply: The role of posterior vitreous detachment on the efficacy of anti-vascular endothelial growth factor intravitreal injection for treatment of neovascular age-related macular degeneration. 61
31546570 2019
32
Delayed Retinal Breaks and Detachments after Acute Posterior Vitreous Detachment. 61
31767432 2019
33
OBSERVATION OF VITREOUS FEATURES USING ENHANCED VITREOUS IMAGING OPTICAL COHERENCE TOMOGRAPHY IN HIGHLY MYOPIC RETINOSCHISIS. 61
29912094 2019
34
Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration. 61
31563866 2019
35
Macular Structure Recovery after Surgery for Optic Disc Pit Maculopathy. 61
31911783 2019
36
Long-term outcomes of patients with myopic traction maculopathy after phacoemulsification for incident cataract. 61
30952957 2019
37
Perfluoro-n-octane-assisted mega Weiss-ring technique for posterior vitreous detachment induction in retinal detachment. 61
31436194 2019
38
Systematic ultrastructural comparison of swept-source and full-depth spectral domain optical coherence tomography imaging of diabetic macular oedema. 61
31473626 2019
39
Point-of-care ultrasound for the evaluation of non-traumatic visual disturbances in the emergency department: The VIGMO protocol. 61
31130372 2019
40
Cost-Effectiveness of Limited Vitrectomy for Vision-Degrading Myodesopsia. 61
30849342 2019
41
Observation of anterior chamber volume after cataract surgery with swept-source optical coherence tomography. 61
30182270 2019
42
Posterior vitreous detachment and incidence of delayed retinal breaks: a retrospective, 2-year study at an academic centre. 61
31358152 2019
43
Characterization of Epiretinal Proliferation in Full-Thickness Macular Holes and Effects on Surgical Outcomes. 61
31104985 2019
44
[Vitreomacular Interface Diseases: Vitreomacular Adhesion, Vitreomacular Traction, Epiretinal Membranes, and Macular Hole]. 61
31416094 2019
45
Effect of vitreomacular adhesion on the treatment outcomes in the STOP-Uveitis clinical trial for non-infectious uveitis. 61
31325001 2019
46
CHANGES IN THE POSTERIOR VITREOUS AFTER CATARACT SURGERY ASSESSED BY SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY. 61
28277441 2019
47
ALTERATIONS OF MACULAR BLOOD FLOW IN SUPERFICIAL AND DEEP CAPILLARY PLEXUSES IN THE FELLOW AND AFFECTED EYES OF PATIENTS WITH UNILATERAL IDIOPATHIC EPIRETINAL MEMBRANE. 61
31305504 2019
48
Ultrasonographic characteristics of active ocular toxoplasmosis. 61
31038555 2019
49
Examiner Position in Ocular Point-of-Care Ultrasound: A Proposed Technique. 61
31003818 2019
50
Symptoms related to posterior vitreous detachment and the risk of developing retinal tears: a systematic review. 61
30632695 2019

Variations for Vitreous Detachment

Expression for Vitreous Detachment

Search GEO for disease gene expression data for Vitreous Detachment.

Pathways for Vitreous Detachment

GO Terms for Vitreous Detachment

Cellular components related to Vitreous Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 VEGFB VEGFA SSC5D PLG PLAT IGFBPL1
2 extracellular region GO:0005576 9.85 VEGFB VEGFA SSC5D PLG PLAT OPTC
3 platelet alpha granule lumen GO:0031093 9.26 VEGFB VEGFA PLG FN1
4 collagen-containing extracellular matrix GO:0062023 9.1 SSC5D PLG PLAT LAMA3 FN1 DPT

Biological processes related to Vitreous Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibrinolysis GO:0042730 9.46 PLG PLAT
2 response to hypoxia GO:0001666 9.46 VEGFB VEGFA PLAT KCNMA1
3 vascular endothelial growth factor signaling pathway GO:0038084 9.43 VEGFB VEGFA
4 induction of positive chemotaxis GO:0050930 9.4 VEGFB VEGFA
5 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.37 VEGFA PLG
6 positive regulation of mast cell chemotaxis GO:0060754 9.32 VEGFB VEGFA
7 interaction with symbiont GO:0051702 9.26 PLG FN1
8 trans-synaptic signaling by BDNF, modulating synaptic transmission GO:0099183 8.96 PLG PLAT
9 platelet degranulation GO:0002576 8.92 VEGFB VEGFA PLG FN1

Molecular functions related to Vitreous Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.56 PLG PLAT LAMA3 FN1
2 fibronectin binding GO:0001968 9.32 VEGFA SSC5D
3 vascular endothelial growth factor receptor binding GO:0005172 9.16 VEGFB VEGFA
4 vascular endothelial growth factor receptor 1 binding GO:0043183 8.96 VEGFB VEGFA
5 extracellular matrix structural constituent GO:0005201 8.92 OPTC LAMA3 FN1 DPT

Sources for Vitreous Detachment

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....